3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Unknown
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Pancreatic Neoplasms
8
Liver Neoplasms
5
Carcinoma, Hepatocellular
4
Lung Neoplasms
3
Squamous Intraepithelial Lesions
2
Prostatic Neoplasms
2
Uterine Cervical Neoplasms
1
Uterine Cervical Dysplasia
1
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Unresectable Pancreatic Cancer
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Rectal Neoplasms
1
Pancreatic Ductal Adenocarcinoma
1
Neoplasm Metastasis
1
Melanoma
1
Lymphatic Metastasis
1
Liver, Cancer of, Non-Resectable
1
Laryngeal Neoplasms
1
Hilus Pulmonary Neoplasms
1
Head and Neck Neoplasms
1
HIV Seropositivity
1
Gallbladder Neoplasms
1
Extremities Neoplasms
1
Esophageal Neoplasms
1
Colorectal Liver Metastases
1
Carcinoma, Renal Cell
1
Interventions
Sunitinib
86
Sorafenib
60
Everolimus
47
pazopanib
46
Bevacizumab
46
Nivolumab
44
pembrolizumab
37
aldesleukin
29
Interferon-alpha
26
Axitinib
24
temsirolimus
23
cabozantinib
20
Interleukin-2
19
Ipilimumab
16
Interferon alpha-2
15
Cyclophosphamide
15
fludarabine phosphate
14
Gemcitabine
14
Peripheral Blood Stem Cell Transplantation
11
Sirolimus
10
Paclitaxel
10
Erlotinib Hydrochloride
10
avelumab
8
Radiosurgery
8
Docetaxel
8
Cyclosporine
8
Capecitabine
8
tremelimumab
7
lenvatinib
7
Mycophenolic Acid
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Carcinoma, Renal Cell
×
Electroporation
×
Clear all
NCT02335827
2021-09-05
IRE
Fuda Cancer Hospital, Guangzhou
Phase NA
Completed
15 enrolled